Dr. Park on ​the Benefits of Off-the-Shelf CAR T-Cell Therapy in ALL

Video

Jae Park, MD, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses ​the benefits of off-the-shelf CAR T-cell therapy in acute lymphoblastic leukemia (ALL).

Patients with low lymphocyte counts after chemotherapy or allogeneic stem cell transplantation ​could benefit from off-the-shelf CAR T-cell products as collecting T cells can be challenging, says Park.

Moreover, patients may experience disease progression during the 3 to 4-week period of T-cell generation that may be mitigated by an off-the-shelf option, concludes Park.

Recent Videos
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Cassandra Gorsuch, PhD, chief scientific officer at Precision
Linda Marbán, PhD, the CEO of Capricor Therapeutics
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Matthew Wicklund, MD, a professor of neurology at the University of Texas Health Science Center San Antonio
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
Renier Brentjens, MD, PhD, the chair of the department of medicine and the deputy director at Roswell Park Comprehensive Cancer Center
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
© 2025 MJH Life Sciences

All rights reserved.